A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease
Status:
Withdrawn
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
Diabetic Nephropathy and other proteinuric renal diseases are the major cause of kidney
disease in the United States. The degree of proteinuria is associated with risk for renal
disease progression and cardiovascular outcomes. Deficiency of 1-25 Vitamin D develops early
in CKD, and is undertreated. Vitamin D may have important effects on factors that drive
proteinuria and renal disease progression in patients with proteinuric renal diseases.
Therefore, Paricalcitol treatment may reduce proteinuria and slow renal deterioration.